Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03873610

Resiliency Training in Adolescents With NF1 and NF2

Resiliency Training in Adolescents With NF1 and NF2; A Randomized Controlled Trial Via Secure Live Video Conferencing to Improve Emotional, Social and Physical Function

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
12 Years – 17 Years
Healthy volunteers
Accepted

Summary

This randomized controlled trial for resiliency training in adolescents with Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom management programs. Both programs are 8 week group programs.

Detailed description

Neurofibromatosis (NFs) are rare genetic conditions with cure. Adolescents with NF experience more symptoms of depression and anxiety, higher levels of stress associated with coping with NF symptoms, lower levels of self esteem, difficulties with social skills and social support, high rates of learning disabilities, and more pain as compared with the general population norms. The aims of this study are to compare the effect of two stress and symptom management programs tailored for adolescents with neurofibromatosis on quality of life and psychosocial functioning. We will also examine the degree to which treatment-dependent improvements in quality of life are mediated by improvements in depression, pain intensity and pain interference.

Conditions

Interventions

TypeNameDescription
BEHAVIORALStress and Symptom Management Program 1The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
BEHAVIORALStress and Symptom Management Program 2The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.

Timeline

Start date
2019-12-15
Primary completion
2026-02-20
Completion
2026-02-20
First posted
2019-03-13
Last updated
2025-12-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03873610. Inclusion in this directory is not an endorsement.